Search

Your search keyword '"Czlonkowska, A"' showing total 1,440 results

Search Constraints

Start Over You searched for: Author "Czlonkowska, A" Remove constraint Author: "Czlonkowska, A"
1,440 results on '"Czlonkowska, A"'

Search Results

1. Carbonated Beverage, Fruit Drink, and Water Consumption and Risk of Acute Stroke: the INTERSTROKE Case-Control Study

2. A Century of Progress on Wilson Disease and the Enduring Challenges of Genetics, Diagnosis, and Treatment

3. Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets

5. Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targets

6. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial

7. Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: a case–control study

8. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

9. Diagnosis of Wilson Disease and Its Phenotypes by Using Artificial Intelligence.

10. Global Impact of COVID-19 on Stroke Care and IV Thrombolysis.

11. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission

13. mtDNA depletion‐like syndrome in Wilson disease

14. Diagnóstico de la enfermedad de Wilson y sus fenotipos usando inteligencia artificial

15. Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality

17. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial

18. Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes.

19. Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature.

20. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention

22. Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality

23. Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)

24. Tea and coffee consumption and risk of acute stroke: The INTERSTROKE Study.

25. Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial

27. Antiplatelet drugs and liver fibrosis

28. Epigenetic changes of the thioredoxin system in the tx-j mouse model and in patients with Wilson disease.

30. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy

32. Blood pressure variability in acute stroke: Risk factors and association with functional outcomes at 1 month.

33. Variations in the prevalence of atrial fibrillation, and in the strength of its association with ischemic stroke, in countries with different income levels: INTERSTROKE case–control study.

35. Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial

37. Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial

38. A Century of Progress on Wilson Disease and the Enduring Challenges of Genetics, Diagnosis, and Treatment

39. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission

40. Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19

41. Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial

42. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

44. Social and demographic characteristics of a Polish cohort with Wilson disease and the impact of treatment persistence

46. Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial

47. Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial

50. International study: Global impact of COVID-19 on stroke care — the Polish contribution

Catalog

Books, media, physical & digital resources